We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
06 Feb 2023 - 09 Feb 2023

Two Tau Variants Distinguish Corticobasal Degeneration from Other Tauopathies

By LabMedica International staff writers
Posted on 28 Nov 2022
Print article
Image: Corticobasal degeneration (CBD): diagram of the basal ganglia (in red) and related structures (in blue) within the brain. Basal ganglia along with cerebral cortex are involved in this condition (Photo courtesy of Wikimedia Commons)
Image: Corticobasal degeneration (CBD): diagram of the basal ganglia (in red) and related structures (in blue) within the brain. Basal ganglia along with cerebral cortex are involved in this condition (Photo courtesy of Wikimedia Commons)

Biomarkers have been found that identify, with up to 89% accuracy, individuals with the primary tauopathy, corticobasal degeneration.

Tauopathies are a heterogeneous group of neurodegenerative diseases that all include aggregated tau proteins. The symptomatic phases of these fatal illnesses involve neurological impairments that typically progress over years to decades, leading to substantial medical, social, and financial burden on patients and families.

Corticobasal degeneration (CBD) is a rare neurodegenerative disease involving the cerebral cortex and the basal ganglia. CBD symptoms typically begin in people from 50 to 70 years of age, and the average disease duration is six years. It is characterized by marked disorders in movement and cognition, and is classified as one of the Parkinson plus syndromes. Diagnosis is difficult, as symptoms are often similar to those of other disorders, such as Parkinson's disease, progressive supranuclear palsy, and dementia with Lewy bodies, and a definitive diagnosis of CBD can only be made upon neuropathologic examination.

Seeking a better method for diagnosing CBD, investigators at Washington University School of Medicine (St. Louis, MO, USA) used an immunoprecipitation technique followed by mass spectrometry to examine brain tissues and cerebrospinal fluid from patients who had died with dementia and movement disorders, and whose specific diseases had been confirmed at autopsy. The study population included patients with one of five primary tauopathies: CBD; progressive supranuclear palsy (PSP); frontotemporal lobar degeneration with microtubule association protein tau mutations (FTLD-MAPT); agyrophilic grain disease; and Pick's disease, as well as Alzheimer's disease, and dementia not related to tau. For comparison, samples from individuals without dementia were also examined.

Results revealed that two particular forms of tau, microtubule binding region (MTBR)-tau 275 and MTBR-tau 282, were unusually prevalent in the brains and reduced in the cerebrospinal fluid of patients with CBD and a subset of FTLD-MAPT. Furthermore these forms of tau distinguished patients with CBD from those with other primary tauopathies with 84% to 89% accuracy, depending on the disease.

"Before, the only way to find out which primary tauopathy a person had was to wait until they died and then examine the person's brain under a microscope," said senior author Dr. Chihiro Sato, assistant professor of neurology at Washington University School of Medicine. "A patient comes in with stiffness, balance problems, slurred speech, and memory issues, and it could be CBD, but it also could be progressive supranuclear palsy (PSP) or Alzheimer's or other diseases. This biomarker can reliably identify people with CBD, which means we can use it to enroll people in clinical trials. And, down the road, it may be key to initiating therapies."

The CBD study was published in the November 24, 2022, online edition of the journal Nature Medicine.

Related Links:
Washington University School of Medicine

 

Gold Supplier
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
New
FOB Rapid Test Strip
FOB Rapid Test
New
STREP A Test
Detector STREP A
New
LED Microscope
DM2000/ DM2000 LED

Print article
MEDLAB - INFORMA

Channels

Immunology

view channel
Image: Histopathology of Langerhans cell histiocytosis: The variation in nuclear contours of these cells is evident in this lesion. Classic `kidney bean` nuclei of Langerhans cells with a central groove are present (Photo courtesy of John Lazarchick, MD)

Cooperativity Between Myeloid Lineages Promotes Langerhans Cell Histiocytosis Pathology

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasia seen in children and adults who present with lesions composed of pathologic variants of myeloid cells that share certain phenotypic... Read more

Microbiology

view channel
Image: Medical illustration of Carbapenem-resistant Enterobacteriacea (Photo courtesy of CDC, Stephanie Rossow)

Breakthrough Test Enables Targeted Antibiotic Therapy for Various Enterobacter Species

Bacteria of the Enterobacter genus are considered to be the most dangerous bacteria linked to hospital infections across the world. Some of their representatives demonstrate high resistance to commonly-used... Read more

Technology

view channel
Image: Flexible copper sensor made cheaply from ordinary materials (Photo courtesy of University of São Paulo)

Low-Cost Portable Sensor Detects Heavy Metals in Sweat

Heavy metals like lead and cadmium can be found in batteries, cosmetics, food and many other things that have become a part of daily life. However, they become toxic if they accumulate in the human body... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.